dsco Discovery Laboratories Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : dsco Discovery Laboratories

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Phil Cressman who started this subject	12/22/2003 12:12:24 PM
From: John McCarthy	of 318

11:58AM Discovery Labs target raised to $20 at Brean Murray (DSCO) 9.35 +0.05: Brean Murray reiterates their Strong Buy rating and raises their target to $20 from $12; firm has reviewed dozens of papers and abstracts involving ARDS patients treated with surfactants over the past week, and have concluded that their initial skepticism of ARDS success may not be warranted, and that the available data are informative enough to allow DSCO to design a trial that is likely to succeed where others have failed; firm thinks that the release of Phase IIb ARDS data is the next most significant catalyst for DSCO. finance.yahoo.com John McCarthy

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next